MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
February 24, 2022 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash...
Update on Tyvaso DPI™ New Drug Application
February 24, 2022 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
February 21, 2022 09:05 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its...
MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
February 10, 2022 06:05 ET
|
MannKind
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
January 05, 2022 06:10 ET
|
MannKind
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
January 05, 2022 06:05 ET
|
MannKind
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind’s CEO appointed as a member of the Thirona...
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
December 06, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Corporation Reports 2021 Third Quarter Financial Results
November 09, 2021 16:05 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash...
Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
November 09, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
November 05, 2021 07:05 ET
|
MannKind
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in...